Acetazolamide

Spécifications

59-66-5Numéro CAS

200-440-5Numéro CE

N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamideNom IUPAC

C4H6N4O3S2Formule chimique

222.3 g/molMasse molaire

acetazolamide; 59-66-5; Acetamox; Glaupax; Edemox; N-(5-Sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide; Acetazolamid; Defiltran; Nephramide; Diacarb; Donmox; Cidamex; Diluran; Phonurit; Didoc; Dehydratin; Diuramid; Diuriwas; Diutazol; Diakarb; Natrionex; Nephramid; Duiramid; Eumicton; Fonurit; Glupax; 5-Acetamido-1,3,4-thiadiazole-2-sulfonamide; Acetazolamida; Acetazolamidum; Acetazoleamide; Diureticum-holzinger; Acetamidothiadiazolesulfonamide; 4-Diamox; Atenezo; Acetamide, N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]-; Carbonic Anhydrase Inhibitor No. 6063; 2-Acetylamino-1,3,4-thiadiazole-5-sulfonamide; DTXSID7022544; 2-Acetamido-5-sulfonamido-1,3,4-thiadiazole; N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide; 1,3,4-Thiadiazole-2-sulfonamide, 5-acetamido-; 5-Acetamide-1,3,4-thiadiazole-2-sulfonamide; N-(5-(Aminosulfonyl)-1,3,4-thiadiazol-2-yl)acetamide; NSC-145177; O3FX965V0I; Acetamide, N-(5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl)-; Acetamide, N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)-; DTXCID002544; CHEBI:27690; 5-acetylamino-1,3,4-thiadiazole-2-sulfonamide; L 579486; NSC145177; HumaZolamide; ApoAcetazolamide; Huma Zolamide; AkZol; Apo Acetazolamide; Ak Zol; N-[5-(aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide; N-(5-(aminosulfonyl)-1,3,5-thiadiazol-2-yl)acetamide; Eytazox; Diamox sr; RefChem:5507; Acetazolamide Extended-Release; S01EC01; 200-440-5; Diamox; Vetamox; SK-acetazolamide; Acetozalamide; C4H6N4O3S2; Carbonic anhydrase inhibitor 6063; NSC 145177; Acetazolamide (Standard); CHEMBL20; MFCD00003105; Diamox (TN); MLS000028435; CAS-59-66-5; NCGC00015074-10; Acetazolamine; Atenezol; Glaumox; SMR000058394; Diamox Sequels; 2-ACETAMIDO-1,3,4-THIADIAZOLE-5-SULFONAMIDE; Acetazolamidum [INN-Latin]; Acetazolamida [INN-Spanish]; CCRIS 5811; Acetazolamide (AAZ); HSDB 3002; SR-01000000065; EINECS 200-440-5; UNII-O3FX965V0I; AI3-52458; Acetazolamide RS; Prestwick_4; 1azm; 1yda; 1ydb; 1ydd; 1zsb; 2xtk; 3czv; 3ucj; Acetazolamide CRS; Acetazolamide, 5; Acetazolamide [USP:INN:BAN:JAN]; Acerazolamide, AAZ; Acetazolamide, AAZ; Acetazolamide, AZA; Acetazolamide, AZM; Spectrum_000018; 1jd0; 2h4n; 2uy4; 3dc3; 3hs4; 3ml5; 4g0c; Opera_ID_288; AZA2; Prestwick0_000003; Prestwick1_000003; Prestwick2_000003; Prestwick3_000003; Spectrum2_000082; Spectrum3_000284; Spectrum4_000139; Spectrum5_000738; Lopac-A-6011; ACETAZOLAMIDE [MI]; A 6011; ACETAZOLAMIDE [INN]; ACETAZOLAMIDE [JAN]; ACETAZOLAMIDE [HSDB]; Lopac0_000039; SCHEMBL23219; ACETAZOLAMIDE [VANDF]; BSPBio_000005; BSPBio_001788; KBioGR_000558; KBioSS_000358; MLS001148438; orb341938; ACETAZOLAMIDE [MART.]; BIDD:GT0643; DivK1c_000017; SPECTRUM1500102; N-(5-Sulfamoyl-[1,3,4]thiadiazol-2-yl)-acetamide; SPBio_000004; SPBio_001926; ACETAZOLAMIDE [USP-RS]; ACETAZOLAMIDE [WHO-DD]; ACETAZOLAMIDE [WHO-IP]; BPBio1_000007; GTPL6792; orb2815843; orb3139251; Acetazolamide, >=99%, powder; SCHEMBL11049053; BDBM10880; BZKPWHYZMXOIDC-UHFFFAOYSA-; HMS500A19; HY-B0782R; KBio1_000017; KBio2_000358; KBio2_002926; KBio2_005494; KBio3_001288; Acetazolamide (JP18/USP/INN); Acetazolamide, analytical standard; NINDS_000017; HMS1568A07; HMS1920A05; HMS2091G05; HMS2095A07; HMS2232G23; HMS3259I13; HMS3260G19; HMS3370P01; HMS3712A07; HMS3744A21; HMS5083D03; Pharmakon1600-01500102; WLN: T5NN DSJ CSZW EMV1; ACETAZOLAMIDE [EP IMPURITY]; ACETAZOLAMIDE [ORANGE BOOK]; ALBB-023617; HY-B0782; MSK10519; ACETAZOLAMIDE [EP MONOGRAPH]; Tox21_110078; Tox21_201559; Tox21_302773; Tox21_500039; ACETAZOLAMIDE [USP MONOGRAPH]; CCG-38900; EBC-03431; NSC755854; s4506; SBB056640; ACETAZOLAMIDUM [WHO-IP LATIN]; AKOS000715163; Tox21_110078_1; CS-3568; DB00819; FA16948; LP00039; NC00491; NSC-755854; SDCCGSBI-0050028.P005; Acetazolamide for system suitability CRS; IDI1_000017; NCGC00015074-01; NCGC00015074-02; NCGC00015074-03; NCGC00015074-04; NCGC00015074-05; NCGC00015074-06; NCGC00015074-07; NCGC00015074-08; NCGC00015074-09; NCGC00015074-11; NCGC00015074-12; NCGC00015074-14; NCGC00015074-15; NCGC00015074-17; NCGC00015074-22; NCGC00023455-03; NCGC00023455-04; NCGC00023455-05; NCGC00023455-06; NCGC00023455-07; NCGC00256374-01; NCGC00259108-01; NCGC00260724-01; AC-12779; AS-13169; SBI-0050028.P004; 2-Acetamido-5-sulfonamido-1,4-thiadiazole; 5-Acetamide-1,4-thiadiazole-2-sulfonamide; DB-053437; 5-Acetamido-1,3,4-thiadiazol-2-sulfonamide; A2598; AB00051906; CS-0694998; EU-0100039; NS00008947; ST45022057; T0813; 1,4-Thiadiazole-2-sulfonamide, 5-acetamido-; C06805; D00218; D88526; EN300-119493; AB00051906_15; Q413690; SR-01000000065-2; SR-01000000065-4; SR-01000000065-6; BRD-K43457670-001-22-9; BRD-K43457670-001-26-0; BRD-K43457670-001-27-8; N-[5-Aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide; Z277559108; (1z)-N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)ethanimidic acid; Acetazolamide, European Pharmacopoeia (EP) Reference Standard; Acetazolamide, United States Pharmacopeia (USP) Reference Standard; Acetazolamide for system suitability, European Pharmacopoeia (EP) Reference Standard; Acetazolamide, Pharmaceutical Secondary Standard; Certified Reference Material; 124442-28-0; 5-Acetamido-1,3,4-thiadiazole-2-sulfonamide;N-(5-[Aminosulfonyl]-1,3,4-thiadiazol-2-yl)acetamide;N-(5-Sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide; InChI=1/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)Synonymes